Phase II Study to Evaluate the Efficacy and Safety of Human, Alpha-1 Antitrypsin (AAT) [Glassia®] in the Treatment of New Onset Type-1 Diabetes

Trial Profile

Phase II Study to Evaluate the Efficacy and Safety of Human, Alpha-1 Antitrypsin (AAT) [Glassia®] in the Treatment of New Onset Type-1 Diabetes

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 13 Nov 2017

At a glance

  • Drugs Alpha 1-antitrypsin (Primary)
  • Indications Type 1 diabetes mellitus
  • Focus Registrational; Therapeutic Use
  • Sponsors Kamada
  • Most Recent Events

    • 13 Nov 2017 According to a Kamada media release, based on the data from this trial, the company and external leaders believe that further studies in a larger population are warranted.
    • 01 Nov 2017 Results presented in a Kamada media release.
    • 01 Aug 2017 According to a Kamada media release, top-line results are anticipated in the second half of 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top